Holen Sie sich die Stockscreener-App
207.04
1.89%
3.84
Handel nachbörslich:
207.04
Schlusskurs vom Vortag:
$203.20
Offen:
$204.33
24-Stunden-Volumen:
1.20M
Relative Volume:
0.73
Marktkapitalisierung:
$34.55B
Einnahmen:
$16.63B
Nettoeinkommen (Verlust:
$1.39B
KGV:
25.66
EPS:
8.0674
Netto-Cashflow:
$2.12B
1W Leistung:
+11.06%
1M Leistung:
+14.61%
6M Leistung:
-8.13%
1J Leistung:
+25.75%
1-Tages-Spanne:
$203.94
$208.29
1-Wochen-Bereich:
$185.43
$208.29
52-Wochen-Spanne:
$154.50
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Firmenname
Iqvia Holdings Inc
Sektor
Branche
Telefon
919-998-2000
Adresse
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, NTRA, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
207.04 | 32.25B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
523.44 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
197.93 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.80 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
279.32 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
379.29 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-03-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2026-03-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-11-03 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-13 | Eingeleitet | BTIG Research | Buy |
| 2023-11-02 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-03-17 | Eingeleitet | Truist | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-11-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-16 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-07-07 | Eingeleitet | Stephens | Equal-Weight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Hochstufung | CFRA | Sell → Hold |
| 2019-11-14 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-05-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-10-02 | Bestätigt | Robert W. Baird | Outperform |
| 2018-07-25 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Bestätigt | Stifel | Buy |
| 2018-07-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Hochstufung | Goldman | Neutral → Buy |
| 2018-03-07 | Hochstufung | SunTrust | Hold → Buy |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Iqvia Holdings Inc Aktie (IQV) Neueste Nachrichten
IQVIA Holdings Inc (IQV) Stock Up 5.2% and Still Undervalued -- GF Score: 90/100 - GuruFocus
IQVIA Holdings highlights its data-driven healthcare platform. Investors focus on long-term growth p - AD HOC NEWS
Baird Adjusts Price Target on IQVIA Holdings Inc to $249 From $230, Maintains Outperform Rating - marketscreener.com
The IQVIA MedTech Acceleratordata-driven support for smaller device makers - AD HOC NEWS
IQVIQVIA Holdings Inc Latest SEC Filings - Finviz
Are Wall Street analysts predicting IQVIA Holdings stock will climb or sink? - MSN
IQVIA Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
IQVIA Holdings updates AI-powered analytics push, shares on NYSE radar - AD HOC NEWS
IQVIA Life Sciences Hub from IQVIA Holdingsunified data backbone for pharma teams - AD HOC NEWS
The Orchestrated Patient Recruitment from IQVIA Holdings Inc.data-driven outreach for tough trial - AD HOC NEWS
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA Holdings Inc Actuals & Estimates (NYSE:IQV) - TradingView
IQVIA Holdings EPS outlook lifted, shares anchored in S&P 500 healthcare tech - Ad-hoc-news.de
(IQV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Charles River upgraded, IQVIA downgraded as Morgan Stanley revisits CRO coverage - MSN
IQVIA Holdings consensus stays constructive, shares trade near record territory - Ad-hoc-news.de
IQV Forecast — Price Target — Prediction for 2027 - TradingView
QTS Forecast — Price Target — Prediction for 2027 - TradingView
IQVIA Holdings chart picture stays robust, shares above key 200-day mark - Ad-hoc-news.de
Is IQVIA (IQV) Balancing Slower Revenue Momentum With Its Latest Debt Refinancing Move? - Sahm
IQVIA Holdings Inc (IQV) Shares Surge 8.4% -- What GF Score of 8 - GuruFocus
IQVIA Holdings Jumps 7.4% Amid Sector-Wide Rally - AlphaStreet
Barclays Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA - Forbes
Pharmacovigilance Automation Market Size to Reach USD 5.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
OCE from IQVIA Holdings Inc.cloud CRM that speaks pharma’s language - Ad-hoc-news.de
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story? - Yahoo Finance
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
IQVIA Holdings trades in a tight range, technicals flag cautious signal for the shares - AD HOC NEWS
IQVIA Holdings Inc (IQV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IQVIA Holdings analyst views shift, shares trade below recent targets - Ad-hoc-news.de
IQVIA Holdings, Inc. (IQV): Investor Outlook On A 34% Potential Upside - DirectorsTalk Interviews
IQVIA Holdings Inc (IQV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IQVIA HoldingsAnalyst consensus and long-term drivers - AD HOC NEWS
Why IQVIA’s Orchestrated Customer Engagement quietly shapes pharma sales - AD HOC NEWS
IQVIA Holdings StockMorgan Stanley cuts rating and trims target - Ad-hoc-news.de
Morgan Stanley Maintains IQVIA Holdings(IQV.US) With Hold Rating, Raises Target Price to $225 - Moomoo
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
IQVIA Holdings Inc (IQV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IQVIA Holdings Inc (IQV) Valuation: PE, PB & Fair Value Analysis - TradingKey
IQVIA Holdings Inc (IQV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IQVIA Holdings Inc (IQV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IQVIA Holdings Inc (IQV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Saratoga Health & Biotechnology Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
IQVIA Holdings Inc (IQV) Institutional Confidence - TradingKey
IQVIA Holdings Inc (IQV) Stock Price, Trades & News - GuruFocus
Is IQVIA Holdings Inc (IQV) a Bargain After 4.7% Drop? GF Value Says Undervalued - GuruFocus
IQVIA Holdings Inc (IQV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IQVIA Holdings, Inc. Stock 12‑Month Price Target Cut to $223.28, Implies 25% Upside - TradingView
Finanzdaten der Iqvia Holdings Inc-Aktie (IQV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):